|
|
HER-2过表达型乳腺癌新辅助治疗1例
|
Abstract:
乳腺癌居女性恶性肿瘤发病率的第1位，人类表皮生长因子受体2 (human epiderma growth factor receptor-2, HER-2)过表达型的患者病情进展迅速，易发生淋巴结、骨骼、脑等多器官转移。本文回顾性分析1例临床分期为T4N1M0的HER-2过表达型乳腺癌患者，新辅助化疗、靶向治疗后行乳腺癌根治术，术后病理分期为ypTisN0M0，后行化疗、靶向及放疗，观察其疗效，并回顾分析相关文献。该患者随诊至今暂无转移复发。
Breast cancer ranks the first place in the incidence of female malignant tumors. Patients with HER-2 over-expressing breast cancer progress rapidly, and lymph node, bone, brain and other organs are prone to metastasis. A case of HER-2 over-expressing breast cancer with clinical stage of T4N1M0 was retrospectively analyzed. After neoadjuvant chemotherapy and targeted therapy, modified radical mastectomy was performed. The pathological stage was ypTisN0M0, and then followed by chemotherapy, targeted therapy and radiotherapy. The patient has no metastasis or recurrence.
| [1] | Marra, A., Chandarlapaty, S. and Modi, S. (2024) Management of Patients with Advanced-Stage HER2-Positive Breast Cancer: Current Evidence and Future Perspectives. Nature Reviews Clinical Oncology, 21, 185-202. https://doi.org/10.1038/s41571-023-00849-9 |
| [2] | Wildiers, H., Tryfonidis, K., Dal Lago, L., Vuylsteke, P., Curigliano, G., Waters, S., et al. (2018) Pertuzumab and Trastuzumab with or without Metronomic Chemotherapy for Older Patients with HER2-Positive Metastatic Breast Cancer (EORTC 75111-10114): An Open-Label, Randomised, Phase 2 Trial from the Elderly Task Force/Breast Cancer Group. The Lancet Oncology, 19, 323-336. https://doi.org/10.1016/s1470-2045(18)30083-4 |
| [3] | Donnelly, S.M., Paplomata, E., Peake, B.M., Sanabria, E., Chen, Z. and Nahta, R. (2013) P38 MAPK Contributes to Resistance and Invasiveness of HER2-Overexpressing Breast Cancer. Current Medicinal Chemistry, 21, 501-510. https://doi.org/10.2174/0929867320666131119155023 |
| [4] | Chariyalertsak, S., Purisa, W. and Vinyuvat, S. (2011) HER-2/Neu Amplification Determined by Real-Time Quantitative PCR and Its Association with Clinical Outcome of Breast Cancer in Thailand. Asian Pacific Journal of Cancer Prevention, 12, 1703-1706. |
| [5] | Yang, Q., Chen, J., Li, H.J., Yu, M., Tian, C.X. and Lü, Q. (2011) Clinical Features and Prognosis Analysis of Different Breast Cancer Molecular Subtypes. Chinese Journal of Oncology, 33, 42-46. |
| [6] | Harbeck, N. and Gnant, M. (2017) Breast Cancer. The Lancet, 389, 1134-1150. https://doi.org/10.1016/s0140-6736(16)31891-8 |
| [7] | 邵志敏. 中国抗癌协会乳腺癌诊治指南与规范(2024年版) [J]. 中国癌症杂志, 2023, 33(12): 1092-1186. |
| [8] | Melichar, B., Hornychová, H., Kalábová, H., Bašová, H., Mergancová, J., Urminská, H., et al. (2012) Increased Efficacy of a Dose-Dense Regimen of Neoadjuvant Chemotherapy in Breast Carcinoma: A Retrospective Analysis. Medical Oncology, 29, 2577-2585. https://doi.org/10.1007/s12032-012-0195-y |
| [9] | Carey, L.A., Dees, E.C., Sawyer, L., Gatti, L., Moore, D.T., Collichio, F., et al. (2007) The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes. Clinical Cancer Research, 13, 2329-2334. https://doi.org/10.1158/1078-0432.ccr-06-1109 |
| [10] | Patani, N. and Mokbel, K. (2010) Herceptin and Breast Cancer: An Overview for Surgeons. Surgical Oncology, 19, e11-e21. https://doi.org/10.1016/j.suronc.2008.11.001 |
| [11] | Gianni, L., Pienkowski, T., Im, Y., Roman, L., Tseng, L., Liu, M., et al. (2012) Efficacy and Safety of Neoadjuvant Pertuzumab and Trastuzumab in Women with Locally Advanced, Inflammatory, or Early HER2-Positive Breast Cancer (NeoSphere): A Randomised Multicentre, Open-Label, Phase 2 Trial. The Lancet Oncology, 13, 25-32. https://doi.org/10.1016/s1470-2045(11)70336-9 |
| [12] | Hurvitz, S.A., Martin, M., Symmans, W.F., Jung, K.H., Huang, C., Thompson, A.M., et al. (2018) Neoadjuvant Trastuzumab, Pertuzumab, and Chemotherapy versus Trastuzumab Emtansine plus Pertuzumab in Patients with HER2-Positive Breast Cancer (KRISTINE): A Randomised, Open-Label, Multicentre, Phase 3 Trial. The Lancet Oncology, 19, 115-126. https://doi.org/10.1016/s1470-2045(17)30716-7 |
